Singapore, 18 April 2024— Horizon Quantum Computing, a company building software development tools for quantum computers, today announced that it is establishing a first-of-a-kind testbed for integrating quantum computing hardware with...
CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
BURLINGTON, Mass., May 6, 2015 – CoLucid Pharmaceuticals, Inc. ("CoLucid") (CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.00 per share.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.